

Protecting and Improving the Health of Iowans

Kim Reynolds, Governor

Adam Gregg, Lt. Governor

Kelly Garcia, Interim Director

COVID-19 Vaccine Information Brief

July 22, 2022

Changes to the document from the previous version are highlighted in yellow.

NEW COVID-19 Vaccine Information - Novavax COVID-19 Vaccine, Adjuvanted

- ACIP Recommends Novavax COVID-19 Vaccine, Adjuvanted for Individuals 18 Years of Age and Older
- Novavax Vaccine
 - Novavax Vaccine Dosage
- Novavax Vaccine Storage and Handling
 - Shipping
 - Storage of Upunctured Vials
 - Storage after First Puncture of Vials
 - Additional Storage and Handling Requirements
- Novavax COVID-19 Vaccination Schedule
- COVID-19 Vaccine Coadministration
- COVID-19 Vaccine Recommendations
- Types of COVID-19 Vaccines
- V-Safe After Vaccination Health Checker

ACIP Recommends Novavax COVID-19 Vaccine, Adjuvanted for Individuals 18 Years of Age and Older

CDC's independent advisory committee, the Advisory Committee on Immunization Practices (ACIP) voted July 19, 2022 to recommend a two-dose Novavax COVID-19 vaccine, Adjuvanted as a COVID-19 primary series for individuals 18 years of age and older. This follows FDA's emergency use authorization (EUA) for Novavax on July 13, 2022. The Novavax COVID-19 vaccine is the first COVID-19 protein subunit vaccine recommended for use in the United States. Having multiple types of vaccines offers more options and flexibility for people receiving COVID-19 vaccines, as well as vaccine providers.

 Novavax COVID-19 Vaccine, Adjuvanted for Individuals 18 Years of Age and Older is anticipated to be available for the July 25, 2022, vaccine allocation survey.

Resources


- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
- Fact Sheet for Healthcare Providers Administering Vaccine
- Fact Sheet for Recipients and Caregivers
- Letter of Authorization
- Updated web pages for the public including:
 - Novavax COVID-19 Vaccine Overview and Safety | CDC
 - Understanding Protein Subunit COVID-19 Vaccines

- O Stay Up to Date with Your COVID-19 Vaccines | CDC
- o COVID-19 Vaccines for People who are Moderately or Severely Immunocompromised | CDC
- Updated CDC <u>COVID-19 booster tool</u>
- <u>COCA call</u> July 28, 2022; 1pm

Novavax COVID-19 Vaccine, Adjuvant for Individuals 18 Years and Older

Novavax Vaccine Dosage

- The Novavax COVID-19 Vaccine, Adjuvanted is authorized for emergency use to provide a two-dose primary series to individuals 18 years of age and older.
- The primary series of the Novavax COVID-19 Vaccine, Adjuvanted, is two doses (0.5 mL each) given 3 weeks apart as an IM injection.
- Novavax COVID-19 Vaccine, Adjuvanted vaccine formulation is supplied in multiple-dose vials which contain 10 doses of 0.5mL and **DOES NOT** require diluent.



Novavax Vaccine Storage and Handling

Shipping

- The Novavax COVID-19 Vaccine, Adjuvanted is supplied in a carton containing 10 multiple-dose vials
- Each multiple-dose vial contains a maximum of 10 doses of 0.5 mL each

Storage of Upunctured Vials

- Do Not Freeze
- Store the unpunctured multi-dose vial in a refrigerator between 2° to 8°C (36° to 46°F)
- Unpunctured vials may be stored refrigerated between 2°C to 8°C (36°F to 46°F) until expiration

Novavax Label²



• Storage after First Puncture of Vials

- After the first needle puncture, hold the vial between 2° to 25°C (36° to 77°F) for up to 6 hours
- Discard the vial 6 hours after the first puncture
- The vaccine is preservative free and does not require reconstitution or dilution


Additional Storage and Handling Requirements

- o The Novavax COVID-19 vaccine, Adjuvanted vial and carton do not have an expiration date
- To find the expiration date, access <u>NovavaxCovidVaccine.com</u>, navigate to the United States Healthcare Professional section of the website, and enter the lot number printed on the carton or vial into the "Expiry Date Checker" tool¹

² Drugs.com. COVID-19 Vaccine Novavax. https://www.drugs.com/pro/covid-19-vaccine-novavax.html Accessed July 7, 2022



Novavax COVID-19 Vaccination Schedule



¹ CDC. Novavax COVID-19 Vaccine Adjuvanted FAQs for CDC.

Novavax COVID-19 Vaccine Doses NOT Currently Authorized

For people receiving a Novavax COVID 19 Vaccine primary series, the following are **NOT** currently authorized:

- A third primary dose for people who are moderately or severely immunocompromised
- A booster dose using any COVID-19 vaccine is not authorized for individuals who receive a Novavax primary series.

CDC provides clinical guidance for what FDA authorizes; **once authorized,** these doses can be added to the COVID -19 vaccination schedule

COVID-19 Vaccine Mixed Primary Series

- The **same** vaccine product should be used for all doses in the primary series.
- There are limited data on the safety and efficacy of a mixed primary series composed of any combination of Moderna, Novavax, and PfizerBioNTech COVID-19 vaccines.
- If a mixed primary series is inadvertently administered:
 - The series is complete, and doses do not need to be repeated
 - This is considered an error; report to the Vaccine Adverse Event Reporting System (VAERS)
- If a person starts but is unable to complete the primary series with the same COVID-19 vaccine due to a contraindication, any other age appropriate COVID-19 vaccine may be administered to complete the series at a minimum interval of 4 weeks (28 days) from the last COVID dose.
 - This would not need to be reported to VAERS.

COVID-19 Vaccine Coadministration

- In general, COVID-19 vaccines may be administered without regard to timing of other vaccines.
 - ✓ Same day
 - Any time before
 - Any time after
- Routine administration of all age-appropriate doses of vaccines simultaneously is recommended for people for whom no specific contraindications exist at the time of the healthcare visit.
- There are additional considerations for orthopoxvirus vaccines.


- When deciding whether to coadminister another vaccine(s) with COVID-19 vaccine, providers may consider:
 - Whether a person is behind or at risk of becoming behind on recommended vaccines
- ☑ Likelihood of the person returning for another vaccination
- ☑ Person's risk of becoming infected with a vaccine-preventable disease
- Person's risk for severe disease if infected
- Reactogenicity profile of the vaccines
- Additional consideration for orthopoxvirus vaccination:

<u>If orthopoxvirus vaccine administered first:</u> Might consider waiting 4 weeks before receiving a Moderna, Novavax, or Pfizer-BioNTech vaccine



<u>If Moderna, Novavax, or Pfizer-BioNTech</u> <u>administered first:</u>

No minimum interval necessary before receiving orthopoxvirus vaccination for prophylaxis in the setting of an outbreak



Types of COVID-19 Vaccines

mRNA

- Moderna
- Pfizer-BioNTech

Adenovirus vector

Janssen

Protein subunit

Novavax

V-Safe After Vaccination Health Checker

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after an individual receives a COVID-19 vaccination. V-safe web pages feature information on how to register and complete a v-safe health check-in (including step-by-instructions with images), troubleshooting, FAQs, and contact information for technical support. These web pages will be continuously updated with additional resources.

V-safe information sheet and poster: Posted on the Vaccine webpage and available in 5 languages: English, Spanish, Korean, Vietnamese, and Simplified Chinese

V-safe after vaccination health checker website

V-Safe Print Resources

Vaccine Adverse Event Reporting System (VAERS)